Is Compounded Semaglutide Going Away?
Mostly, it already did — back in 2025, when the shortages ended. What is happening now is a different, later step. Here is what FDA has actually proposed, what the July 30, 2026 deadline is, and what none of it changes.
Medically reviewed by Charles Kamen, MD, board-certified neurologist ·
The short answer
If you are asking whether compounded semaglutide is about to disappear, the honest answer is that the decisive change happened more than a year ago and most coverage still has not caught up. Compounding these medicines from bulk ingredient at any scale was permitted largely because they sat on FDA’s drug shortage list. Once FDA declared those shortages resolved — tirzepatide in October 2024, semaglutide in February 2025 — the legal basis went with them, and enforcement discretion wound down on staggered deadlines through spring 2025.
What is live right now is a separate question. On May 1, 2026 FDA published a notice proposing not to add semaglutide, tirzepatide, or liraglutide to the 503B bulks list — the list that permits registered outsourcing facilities to compound from a bulk active ingredient. That proposal would keep a door closed rather than close one that is currently open. It is not final, and the public comment period runs to July 30, 2026 under docket FDA-2018-N-3240.
How we got here
What the July 30, 2026 date actually is
It is a deadline for public comments, not a date on which anything becomes illegal. FDA asked for input on its proposal, originally set the deadline at June 30, 2026, and then extended it on June 26 in response to a request for more time. The extension notice states plainly that comments must be submitted by July 30, 2026 and that late, untimely filed comments will not be considered.
Anyone can file one — patients, prescribers, pharmacists — through regulations.gov under docket FDA-2018-N-3240. After the period closes, FDA weighs the comments and issues a final determination. If you have a view about clinical need here, that is the mechanism that exists for saying so, and it closes in days.
What this does not change
Approved GLP-1 medications are unaffected. Ozempic, Wegovy, Mounjaro and Zepbound are FDA-approved finished products. This proposal is about whether outsourcing facilities may compound from bulk semaglutide, tirzepatide or liraglutide as raw ingredients — a different question entirely. Prescribing and dispensing of the approved products continues as before.
It is also not a statement that compounded versions were equivalent. A compounded preparation is not an FDA-approved drug. It has not been reviewed for safety, effectiveness or manufacturing quality, and the approved product’s labeling does not apply to it. That was true during the shortage and it is true now. We lay out the full comparison on compounded semaglutide versus Ozempic and compounded tirzepatide versus Mounjaro.
One thing worth saying plainly: a comment deadline is not a countdown to stock up. If you are being told online to secure a supply before July 30, that is a misreading of what the date is, and it is not advice that comes from anyone who knows your medical history.
Physician-Led in Las Vegas
Not sure where this leaves you?
An $88 evaluation with Dr. Charles Kamen, MD covers which approved options fit your goals and history, with the regulatory position checked at the time of care rather than from a headline. If a medication is not right for you, you will be told that too.
Compounded GLP-1 FAQ
Is compounded semaglutide going away?
For most people it already went away, and that is the part the headlines keep missing. Compounding these drugs at scale was permitted mainly because they were on FDA’s shortage list. FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, and enforcement discretion ended on staggered deadlines through spring 2025. What is happening now is a separate, later step: FDA has proposed not to add semaglutide, tirzepatide, or liraglutide to the 503B bulks list, which would keep the large-scale door closed rather than close one that is currently open.
What is the July 30, 2026 deadline?
It is the deadline for public comments on FDA’s proposal, not a date on which anything is banned. FDA published the proposal on May 1, 2026 under docket FDA-2018-N-3240 with comments originally due June 30, then extended the period on June 26. Comments must now be submitted by July 30, 2026. Anyone — patients, clinicians, pharmacies — may submit one through regulations.gov. After the period closes FDA considers the comments and issues a final determination; the notice states that late comments will not be considered.
Does this affect Ozempic, Wegovy, Mounjaro, or Zepbound?
No. Those are FDA-approved finished drug products and are not part of this proposal. The proposal concerns whether outsourcing facilities may compound from bulk semaglutide, tirzepatide, or liraglutide as active ingredients. The approved brand products are prescribed and dispensed exactly as before.
What is the difference between 503A and 503B here?
Section 503B covers outsourcing facilities — larger operations registered with FDA that can produce batches without a patient-specific prescription. Section 503A covers traditional state-licensed pharmacies compounding for an individual patient with a valid prescription. This proposal is specifically about the 503B bulks list. 503A compounding is governed by a different set of conditions, and a 503A pharmacy still cannot use a bulk substance simply because it wants to. Neither route produces an FDA-approved drug.
Can I still get a GLP-1 prescription?
Yes. FDA-approved GLP-1 and incretin medications are prescribed by licensed clinicians and dispensed by licensed pharmacies, and none of that is affected by this proposal. What has changed is the availability of compounded versions made from bulk ingredient, which was always a conditional exception rather than the normal pathway.
Is compounded semaglutide the same as the brand version?
No. A compounded preparation is not an FDA-approved drug: it has not been through FDA review for safety, effectiveness, or manufacturing quality, and the approved product’s labeling does not apply to it. We cover the full comparison on our compounded semaglutide versus Ozempic page. Nothing on this page should be read as a recommendation to obtain any compounded product.
Should I stockpile before the deadline?
No, and please do not treat this page as a reason to. The July 30 date is a comment deadline, not a cutoff after which anything becomes unavailable. Decisions about which medication is appropriate for you belong in a conversation with a licensed clinician who knows your history — not in a rush against a regulatory date that does not mean what it is being portrayed to mean online.
Primary sources
Federal Register — proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list (published May 1, 2026) · Federal Register — extension of comment period to July 30, 2026 (published June 26, 2026) · FDA — human drug compounding laws. Both notices are docket FDA-2018-N-3240.
Related reading: Compounded semaglutide vs. Ozempic · 503A vs. 503B compounding · GLP-1 medications compared · Peptide regulatory tracker · GLP-1 therapy in Las Vegas · Semaglutide vs. tirzepatide vs. retatrutide · GLP-1 medications 2026 guide
Scope & compliance: this page reports regulatory status and is not medical or legal advice. It contains no doses and makes no claim that any compounded preparation is safe, effective, or equivalent to an approved product. Regulatory status changes — verify against the linked primary sources at the time of care.
Ready to start your longevity care?
Book your $88 evaluation with Dr. Kamen today, online, by phone, or by text.
Book Your $88 EvaluationPrefer to talk? Call (702) 808-2650 or text us to book.
Physician-led peptide therapy in Las Vegas. Visit our clinicAlso serving Henderson — or explore semaglutide weight loss in Las Vegas.